EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Care Pathways for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A State‐of‐The‐Art Review

Kirsi M A van Eekhout iD, Leonard D Broekman, Vivian D de Jong, Maurice Michel, Rick Grobbee, Douglas Maya-Miles, Manuel Romero-Gómez iD, Jean Muris, Juan M Mendive iD, Yasaman Vali iD, Oscar H Franco, Jörn M Schattenberg iD und 5 weitere

Liver International · 2026-04 · 46 (4)

DOI: 10.1111/liv.70603 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 19.03.2026. Verfasst von Kirsi M A van Eekhout und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Internal Medicine, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Critical Pathways, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Health Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐Associated Steatotic Liver Disease (MASLD) is a growing clinical challenge, necessitating effective diagnostic strategies to identify advanced liver fibrosis while minimising unnecessary referrals of mild cases. Current clinical guidelines recommend care pathways utilising non‐invasive tests (NITs) to stratify patients, but the optimal diagnostic algorithm across care settings remains unclear. This state‐of‐the‐art review systematically examines studies describing clinical care pathways for detecting advanced fibrotic MASLD and stratifying patients at risk. A comprehensive literature search of MEDLINE, Embase, Cochrane Library, and Scopus, finalised in January 2026, identified nine relevant studies that met predefined criteria including structured care plans and applicability beyond diagnosis alone. Pathway populations included patients at risk for MASLD (type 2 diabetes ( n = 4) or broad range cardiometabolic risk factors ( n = 1)) or confirmed MASLD ( n = 4). The most frequently employed NITs were FIB‐4 and vibration‐controlled transient elastography (VCTE). Numbers needed to screen (NNS) for hepatology referral and advanced fibrosis detection varied considerably across pathways and populations, reflecting heterogeneity in design and fibrosis assessment methods. All studies reported improved patient risk stratification; attendance rates declined at each pathway step. Findings suggest that NIT‐based clinical care pathways can effectively align patient management and optimise transmural care for MASLD. Nonetheless, heterogeneity in pathway design and fibrosis determination highlights the need for standardised protocols and validation in larger, at‐risk cohorts to strengthen evidence supporting widespread adoption. This review contributes to advancing MASLD management within evolving clinical frameworks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Critical PathwaysLiver CirrhosisNon-alcoholic Fatty Liver DiseaseFatty LiverHumansElasticity Imaging TechniquesRisk Factors

Stichwörter der Autor:innen

care pathwaychronic liver diseaseliver fibrosismetabolic dysfunction‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Vascular and Internal Medicine, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Global Public Health & Bioethics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Julius Clinical, Zeist, the Netherlands.
  • Department of Internal Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.
  • Saarland University, Saarbrücken, Germany.
  • SeLiver Group, Instituto de Biomedicina de Sevilla/CSIC/Virgen del Rocío University Hospital, University of Seville, Seville, Spain/Centro De Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERE…

ORCID-Profile: Kirsi M A van Eekhout, Manuel Romero-Gómez, Juan M Mendive, Yasaman Vali, Jörn M Schattenberg

Förderung

  • Innovative Health Initiative

Zitieren

APA

van Eekhout, K. M. A., Broekman, L. D., de Jong, V. D., Michel, M., Grobbee, R., Maya-Miles, D., Romero-Gómez, M., Muris, J., Mendive, J. M., Vali, Y., Franco, O. H., Schattenberg, J. M., Fournier-Poizat, C., Castro Cabezas, M., Tushuizen, M. E., Holleboom, A. G., & GRIPonMASH consortium (2026). Care Pathways for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A State‐of‐The‐Art Review. Liver International, 46(4). https://doi.org/10.1111/liv.70603

Vancouver

van Eekhout KMA, Broekman LD, de Jong VD, Michel M, Grobbee R, Maya-Miles D, et al. Care Pathways for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A State‐of‐The‐Art Review. Liver International. 2026;46(4). doi:10.1111/liv.70603

BibTeX
@article{vanEekhout2026,
  author = {van Eekhout, Kirsi M A and Broekman, Leonard D and de Jong, Vivian D and Michel, Maurice and Grobbee, Rick and Maya-Miles, Douglas and Romero-Gómez, Manuel and Muris, Jean and Mendive, Juan M and Vali, Yasaman and Franco, Oscar H and Schattenberg, Jörn M and Fournier-Poizat, Céline and Castro Cabezas, Manuel and Tushuizen, Maarten E and Holleboom, Adriaan G and GRIPonMASH consortium, GRIPonMASH consortium},
  title = {Care Pathways for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A State‐of‐The‐Art Review},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/liv.70603}
}
Kostenlos starten →